Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs a single-antigen hepatitis B vaccine : a phase 3 randomized clinical trial

Autor: Johanna Spaans, Bebi Yassin-Rajkumar, Peter Ruane, Timo Vesikari, Saul N. Faust, Amina Z Haggag, Bruce Rankin, Benita Ukkonen, Michael Levin, Michael Manns, Satu Kokko, Gerald Vallieres, Carl Griffin, David E. Anderson, Vlad Popovic, Francisco Diaz-Mitoma, Mary B Manning, Azhar Toma, Hamilton Sah, Clancy L. Cone, Nathalie Machluf, Nathan Segall, Williams Hayes, Mark A. Turner, Aino Forsten, Outi Laajalahti, Maija Rössi, Anitta Ahonen, Mark E Kutner, Naveen Garg, M N Ramasamy, Adam Finn, Isabel Leroux-Roels, Olli Henriksson, Dennis Reich, Geert Leroux-Roels, Pierre Van Damme, Pauliina Paavola, Catherine Cosgrove, Barbara E. Rizzardi, Ilkka Seppä, Ronnie Aronson, Samir Arora

Publikováno v: JAMA NETWORK OPEN
JAMA Network Open
Vesikari, T, Finn, A, van Damme, P, Leroux-Roels, I, Leroux-Roels, G, Segall, N, Toma, A, Vallieres, G, Aronson, R, Reich, D, Arora, S, Ruane, P J, Cone, C L, Manns, M, Cosgrove, C, Faust, S N, Ramasamy, M N, Machluf, N, Spaans, J N, Yassin-Rajkumar, B, Anderson, D, Popovic, V, Diaz-Mitoma, F 2021, ' Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine : A Phase 3 Randomized Clinical Trial ', JAMA Network Open, vol. 4, no. 10, e2128652, pp. e2128652 . https://doi.org/10.1001/jamanetworkopen.2021.28652
JAMA Netw Open

Importance There is a need for improved immunogenicity of hepatitis B virus (HBV) vaccines among young adults with risk of infection. Objectives To demonstrate manufacturing equivalence of a 3-antigen (3A) HBV vaccine, evaluate noninferiority of sero

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fb4f067c6f9010c585085536e06f1af
https://hdl.handle.net/1854/LU-8759301